Tech Company Financing Transactions
Frontier Medicines Funding Round
Deerfield Management Company, RA Capital and private investors invested in a $80 million Series C funding round for Frontier Medicines. The round was announced on 2/22/2024.
Transaction Overview
Company Name
Announced On
2/22/2024
Transaction Type
Venture Equity
Amount
$80,000,000
Round
Series C
Investors
RA Capital (Derek DiRocco)
Proceeds Purpose
Series C helps to have clinical data in hand when you hit Wall Street, something he expects by the end of this year, teeing up a potential IPO afterward.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
151 Oyster Point Blvd. 2nd Floor
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Frontier Medicines is a pre-clinical stage biopharmaceutical company developing breakthrough medicines that redefine the course of debilitating diseases. Our focus is developing treatments against important cancer-causing proteins that the biopharma industry hasn't found a way to treat (or drug) with pharmaceutical interventions.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Chris Varma
Chief Financial Officer
Gregory Chow
Chief Scientific Officer
Kevin Webster
Chief Technical Officer
Johannes Hermann
Co-Founder
Daniel Nomura
Co-Founder
Roberto Zoncu
Vice President
Daniel Erlanson
Browse more venture capital transactions:
Prev: 2/22/2024: Hellohive venture capital transaction
Next: 2/22/2024: EigenLayer venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to record every notable VC transaction. VC investment data records reported here come from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs